Boothbay Fund Management
ARCT icon

Boothbay Fund Management’s Arcturus Therapeutics ARCT Stock Holding History

Boothbay Fund Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-61,700
Closed -$971K – 2228
2022
Q2 		$971K Buy
+61,700
New +$1.21M 0.03% 832
2021
Q1 		– Sell
-106
Closed -$460K – 1519
2020
Q4 		$460K Buy
+106
New +$7.18K 0.02% 781

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Boothbay Fund Management's ARCT Position: Q3 2025 in Review

Boothbay Fund Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 50,471 shares — an estimated $811K sold.

Boothbay Fund Management first reported a position in ARCT in Q2 2022 and held it in 4 quarters. The position peaked at $1M in Q4 2024. 137 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Boothbay Fund Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 50,471 Arcturus Therapeutics shares in Q3 2025, an estimated $811K.
  • Boothbay Fund Management first reported a position in Arcturus Therapeutics in Q2 2022 and held it in 4 quarters.
  • Boothbay Fund Management's Arcturus Therapeutics position peaked at $1M in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.